Wellington Management Group
CADL icon

Wellington Management Group’s Candel Therapeutics CADL Stock Holding History

Wellington Management Group’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12M Buy
+205,745
New +$1.55M ﹤0.01% 1613
2025
Q4 		– Sell
-137,888
Closed -$703K – 1940
2025
Q3 		$703K Buy
137,888
+51,641
+60% +$298K ﹤0.01% 1840
2025
Q2 		$436K Buy
+86,247
New +$444K ﹤0.01% 1838

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wellington Management Group's CADL Position: Q2 2026 in Review

Wellington Management Group opened a new position in Candel Therapeutics (CADL) in Q2 2026: 205,745 shares worth $2.12M. The stake represents ﹤0.01% of the portfolio and ranks #1613 among its holdings. This is a return to the name: Wellington Management Group previously reported a position in CADL as recently as Q3 2025.

Wellington Management Group first reported a position in CADL in Q2 2025 and has held it in 3 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Wellington Management Group held 205,745 shares of Candel Therapeutics worth $2.12M as of Q2 2026.
  • Candel Therapeutics was a new Wellington Management Group position in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1613 holding.
  • Wellington Management Group first reported a position in Candel Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.